Qube Research & Technologies (QRT)’s Fulcrum Therapeutics FULC Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio FULC Stock Details FULC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.4M	Buy	1,748,467 +773,728	+79%	+$4.71M	0.01%	1512
2026 Q1	$7.48M	Buy	974,739 +582,250	+148%	+$5.4M	0.01%	1459
2025 Q4	$4.44M	Buy	+392,489	New	+$3.99M	﹤0.01%	1836
2024 Q3	–	Sell	-553,307	Closed	-$3.43M	–	3585
2024 Q2	$3.43M	Sell	553,307 -169,856	-23%	-$1.29M	0.01%	1427
2024 Q1	$6.83M	Buy	723,163 +480,255	+198%	+$4.29M	0.01%	1044
2023 Q4	$1.64M	Buy	242,908 +229,842	+1,759%	+$1.02M	﹤0.01%	1643
2023 Q3	$58K	Buy	+13,066	New	+$57.1K	﹤0.01%	2826
2022 Q3	–	Sell	-31,813	Closed	-$156K	–	2668
2022 Q2	$156K	Buy	+31,813	New	+$311K	﹤0.01%	1795

Other funds holding FULC

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Qube Research & Technologies (QRT)'s FULC Position: Q2 2026 in Review

Qube Research & Technologies (QRT) increased its Fulcrum Therapeutics (FULC) stake by 79% in Q2 2026, buying an estimated $4.71M and bringing the position to 1,748,467 shares worth $6.4M. The position accounts for 0.01% of the portfolio, ranked #1512.

Qube Research & Technologies (QRT) first reported a position in FULC in Q2 2022 and has held it in 8 quarters since. The position peaked at $7.48M in Q1 2026. 154 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

Qube Research & Technologies (QRT) held 1,748,467 shares of Fulcrum Therapeutics worth $6.4M as of Q2 2026.
Qube Research & Technologies (QRT) bought 773,728 Fulcrum Therapeutics shares in Q2 2026, an estimated $4.71M.
Fulcrum Therapeutics made up 0.01% of Qube Research & Technologies (QRT)'s portfolio in Q2 2026, its #1512 holding.
Qube Research & Technologies (QRT) first reported a position in Fulcrum Therapeutics in Q2 2022 and has held it in 8 quarters since.
Qube Research & Technologies (QRT)'s Fulcrum Therapeutics position peaked at $7.48M in Q1 2026.
154 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2026, filed 14 Aug 2026.